Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Revestive

- PMLiVE

Takeda opens new UK office in High Wycombe

Hopes move to larger premises will help expand business

- PMLiVE

Takeda loses in lawsuit claiming cancer link to Actos

Ordered to compensate woman who claims drug gave her bladder cancer

- PMLiVE

Second time lucky for Takeda’s obesity drug

FDA approves Contrave three years after initial rejection

- PMLiVE

Takeda: No link between Actos and bladder cancer

Ten-year study backs safety of diabetes drug

- PMLiVE

Takeda drops prostate cancer drug in phase III

Suffers another late-stage pipeline blow as orteronel disappoints

- PMLiVE

Omontys terminal as Takeda switches off support

Japanese company ends anaemia treatment partnership with Affymax

EU flag

EC approves drugs for diabetes and Crohn’s disease

Takeda’s Entyvio and Boehringer/Lilly’s Jardiance get green light

- PMLiVE

Japanese product news in brief

Home launch for Astellas' Xtandi, GSK files COPD drug for approval and more

- PMLiVE

FDA clears Takeda’s vedolizumab for inflammatory bowel disease

Entyvio licensed for patients who have not responded to current therapies

- PMLiVE

US jury says Takeda and Lilly must pay $9bn in Actos damages

Court says companies covered up cancer risks of diabetes drug

- PMLiVE

EU approval for Takeda’s schizophrenia drug

Latuda said to have improved side effect profile compared to other treatments

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links